Aurobindo Pharma is currently trading at Rs. 442.75, up by 5.50 points or 1.26% from its previous closing of Rs. 437.25 on the BSE. The scrip opened at Rs. 440.40 and has touched a high and low of Rs. 444.80 and Rs. 438.40 respectively. So far 102108 shares were traded on the counter. The BSE … Read more
Aurobindo Pharma is currently trading at Rs. 583.95, up by 3.55 points or 0.61% from its previous closing of Rs. 580.40 on the BSE. The scrip opened at Rs. 579.45 and has touched a high and low of Rs. 586.35 and Rs. 566.60 respectively. So far 98079 shares were traded on the counter. The BSE … Read more
Aurobindo Pharma is currently trading at Rs. 596.90, up by 3.60 points or 0.61% from its previous closing of Rs. 593.30 on the BSE. The scrip opened at Rs. 594.00 and has touched a high and low of Rs. 602.75 and Rs. 592.90 respectively. So far 29574 shares were traded on the counter. The BSE … Read more
Aurobindo Pharma is currently trading at Rs. 535.25, up by 6.60 points or 1.25% from its previous closing of Rs. 528.65 on the BSE. The scrip opened at Rs. 532.95 and has touched a high and low of Rs. 537.00 and Rs. 528.50 respectively. So far 8960 shares were traded on the counter. The BSE … Read more
Aurobindo Pharma is currently trading at Rs. 532.75, down by 8.25 points or 1.52% from its previous closing of Rs. 541.00 on the BSE. The scrip opened at Rs. 541.20 and has touched a high and low of Rs. 546.50 and Rs. 527.40 respectively. So far 346162 shares were traded on the counter. The BSE … Read more
Aurobindo Pharma is currently trading at Rs. 728.80, up by 3.65 points or 0.50% from its previous closing of Rs. 725.15 on the BSE. The scrip opened at Rs. 734.60 and has touched a high and low of Rs. 735.30 and Rs. 725.10 respectively. So far 49767 shares were traded on the counter. The BSE … Read more
Aurobindo Pharma’s subsidiary — Eugia Pharma Specialities (Eugia) has received a 505(b)(2) NDA approval from the U.S.Food & Drug Administration (USFDA) for its Cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vials. Aurobindo’s product will be available in ready-to-use (RTU) injection preparation. The product shall be launched in the US market in the near … Read more